A. Hirayama

发表

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

D. Maloney, C. Turtle, S. Riddell, 2020, Blood.

Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells.

M. Bar, M. Sorror, D. Maloney, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

B. Simões, H. Bittencourt, V. Rocha, 2021, Hematology, transfusion and cell therapy.

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients

A. Alencar, P. Scheinberg, M. de Lima, 2021, Hematology, transfusion and cell therapy.

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

M. Sorror, B. Sandmaier, D. Maloney, 2019, Blood advances.

Assessing the importance of interleukin-6 in COVID-19 – Authors' reply

C. Deutschman, C. Turtle, M. Harhay, 2021, The Lancet Respiratory Medicine.

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

C. Deutschman, C. Turtle, M. Harhay, 2020, The Lancet Respiratory Medicine.

Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

M. Bar, D. Maloney, C. Turtle, 2021, JCI insight.

93 PCR assay to identify woodchuck hepatitis virus posttranscriptional regulatory element in CAR-T and TCR-T cells for fresh and formalin-fixed samples

C. Turtle, Jocelyn Wright, J. Specht, 2022, Regular and Young Investigator Award Abstracts.

CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review

C. Blosser, S. Tykodi, C. Yeung, 2022, Bone Marrow Transplantation.

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Toxicities of CD19 CAR‐T cell immunotherapy

C. Turtle, A. Hirayama, 2019, American journal of hematology.

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy

M. Bar, D. Maloney, C. Turtle, 2021, Blood advances.

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.

A. Alencar, V. Rocha, M. de Lima, 2021, Hematology, transfusion and cell therapy.

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.

M. Bar, D. Maloney, C. Turtle, 2020, Blood.

Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.

D. Maloney, C. Turtle, S. Riddell, 2018 .

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

M. Sorror, D. Maloney, C. Turtle, 2022, Blood.

Factors Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy

M. Bar, D. Maloney, C. Turtle, 2020 .

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

D. Maloney, C. Turtle, S. Riddell, 2020 .

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry.

R. Pierce, C. Turtle, A. Rongvaux, 2020, Journal of immunological methods.

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

D. Maloney, C. Turtle, H. Kiem, 2019, Blood.

Anakinra for refractory CRS or ICANS after CAR T-cell therapy.

D. Maloney, C. Turtle, E. Nemecek, 2023, Transplantation and cellular therapy.

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy

C. Turtle, S. Riddell, Simon P. Fraessle, 2022, Blood advances.

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

D. Maloney, C. Turtle, H. Kiem, 2023, Blood advances.

Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy

K. Naresh, V. Wu, Ryan S Basom, 2023, European journal of haematology.

qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue

C. Turtle, A. Chapuis, A. Hirayama, 2024, PloS one.

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

D. Maloney, C. Turtle, R. Maziarz, 2021, Blood.

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

H. Kiem, J. Gauthier, B. Till, 2024, Blood advances.